TransCode expects that its cash of approximately $2.8 million as of December 31, 2023, together with approximately $6.2 million in net proceeds received from the sale of common stock and warrants in a January 2024 registered direct offering, will be sufficient to fund planned operations into late third quarter or early fourth quarter of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAZ:
- TransCode Therapeutics Reports 2023 Results; Provides Business Update
- Transcode Therapeutics announces appointment of Vlock as CMO
- TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
- TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
- Transcode Therapeutics, Akribion report progress on CRISPR-derived tech
